152 related articles for article (PubMed ID: 7348089)
21. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
22. Acutely psychotic patients receiving high-dose haloperidol therapy.
Remington G; Pollock B; Voineskos G; Reed K; Coulter K
J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
[TBL] [Abstract][Full Text] [Related]
23. Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients.
Aschauer HN; Schönbeck G; Langer G; Koinig G; Resch F; Hatzinger R; Chaudry HR; Sieghart W
Pharmacopsychiatry; 1988 Sep; 21(5):246-51. PubMed ID: 3227055
[TBL] [Abstract][Full Text] [Related]
24. Serum haloperidol and neuroleptic receptor levels in chronic psychosis.
Cannon DJ; McMillan DE; Newton JE; Fody EP; Metzer WS; Claybrook M; Couch L; Paige SR
Ann Clin Lab Sci; 1988; 18(5):378-83. PubMed ID: 3178137
[TBL] [Abstract][Full Text] [Related]
25. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
[TBL] [Abstract][Full Text] [Related]
26. [Use of haloperidol at very high doses].
Lavagna J; Lafont A; Darcourt G
Encephale; 1976; 2(4):363-5. PubMed ID: 1001244
[TBL] [Abstract][Full Text] [Related]
27. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
Moleman P; Schmitz PJ; Ladee GA
J Clin Psychiatry; 1982 Dec; 43(12):492-6. PubMed ID: 7161250
[TBL] [Abstract][Full Text] [Related]
28. Relation of serum molindone levels to serum prolactin levels and antipsychotic response.
Pandurangi AK; Narasimhachari N; Blackard WG; Landa BS
J Clin Psychiatry; 1989 Oct; 50(10):379-81. PubMed ID: 2676994
[TBL] [Abstract][Full Text] [Related]
29. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
Altamura AC; Buccio M; Colacurcio F; Colombo G; Terzi A
Acta Neurol (Napoli); 1986 Feb; 8(1):19-26. PubMed ID: 3962752
[No Abstract] [Full Text] [Related]
30. Correlates of early neuroleptic response using a uniform haloperidol dose.
Bowers MB; Swigar ME; Jatlow PI; Hoffman FJ; Goicoechea N
Int Clin Psychopharmacol; 1987 Jul; 2(3):255-60. PubMed ID: 3693868
[TBL] [Abstract][Full Text] [Related]
31. Blood levels of haloperidol in schizophrenic patients.
Shvartsburd A; Dekirmenjian H; Smith RC
J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
[TBL] [Abstract][Full Text] [Related]
32. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
33. Haloperidol and droperidol treatment in schizophrenics. Clinical application of the "prolactin-model".
Langer G; Pühringer W
Acta Psychiatr Belg; 1980; 80(5):574-83. PubMed ID: 7234451
[TBL] [Abstract][Full Text] [Related]
34. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
[TBL] [Abstract][Full Text] [Related]
35. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.
McElroy SL; Keck PE; Stanton SP; Tugrul KC; Bennett JA; Strakowski SM
J Clin Psychiatry; 1996 Apr; 57(4):142-6. PubMed ID: 8601548
[TBL] [Abstract][Full Text] [Related]
36. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
37. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
[TBL] [Abstract][Full Text] [Related]
38. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
[TBL] [Abstract][Full Text] [Related]
39. Drug holidays and serum haloperidol levels in schizophrenic patients.
McMillan DE; Fody EP; Couch L; Harrison RH; Newton JE; Reese WG
J Clin Psychiatry; 1986 Jul; 47(7):373-4. PubMed ID: 3722135
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
Morasiewicz J; Baranowski P; Borys J; Jańska-Skomorowska M; Kiejna A
Psychiatr Pol; 1995; 29(3):405-20. PubMed ID: 7652093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
